# Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

> **NCT03568461** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 98 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** tisagenlecleucel

## Key facts

- **NCT ID:** NCT03568461
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2020-11-24
- **Final completion:** 2025-05-28
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568461, "Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03568461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*